Literature DB >> 22454922

The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics.

A V Mackay1, A F Healey, J Baker.   

Abstract

1 Blood samples were obtained from eighty-six chronic schizophrenics receiving a wide range of oral doses of chlorpromazine. Plasma concentrations of chlorpromazine, 7-hydroxychlorpromazine and chlorpromazine sulphoxide were estimated using a sensitive gas-liquid chromatographic method and their relationships to oral dose and to global clinical control were investigated.2 Wide variability was observed in the plasma concentrations of unchanged drug and metabolites between patients receiving similar daily doses.3 In general the plasma concentrations of the 7-hydroxy and sulphoxide metabolites were of similar magnitude to the concentrations of chlorpromazine.4 Global symptom control was unrelated to the plasma concentration of unchanged chlorpromazine. However, patients judged to be under good control had relatively higher concentrations of the biologically active 7-hydroxy metabolite in their plasma than patients who were poorly controlled and in whom the biologically inactive sulphoxide metabolite predominated. When the ratio of 7-hydroxychlorpromazine to chlorpromazine sulphoxide was derived for each patient, a highly significant difference was found to exist between the metabolite ratios of patients grouped according to clinical control.5 It is suggested that a prediction of therapeutic response to chlorpromazine may be provided in the form of the ratio of the plasma concentration of biologically active metabolite to the concentration of either the unchanged drug or its inactive metabolite.

Entities:  

Year:  1974        PMID: 22454922      PMCID: PMC1402470          DOI: 10.1111/j.1365-2125.1974.tb00281.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Proceedings: Clinical pharmacology of chlorpromazine.

Authors:  S H Curry; M H Lader; G P Mould; G Sakalis
Journal:  Br J Pharmacol       Date:  1972-02       Impact factor: 8.739

2.  The possible role of metabolites in therapeutic response to chlorpromazine treatment.

Authors:  G Sakalis; T L Chan; S Gershon; S Park
Journal:  Psychopharmacologia       Date:  1973-09-28

3.  Chlorpromazine metabolism. V. Disposition of free and conjugated metabolites in blood fractions of schizophrenic patients.

Authors:  P N Kaul; M K Ticku; M L Clark
Journal:  J Pharm Sci       Date:  1972-11       Impact factor: 3.534

4.  Physiologic and clinical effects of chlorpromazine and their relationship to plasma level.

Authors:  G Sakalis; S H Curry; G P Mould; M H Lader
Journal:  Clin Pharmacol Ther       Date:  1972 Nov-Dec       Impact factor: 6.875

5.  Effect of various chlorpromazine metabolites on amphetamine-induced stereotyped behaviour in the rat.

Authors:  S Lal; T L Sourkes
Journal:  Eur J Pharmacol       Date:  1972-02       Impact factor: 4.432

6.  Chlorpromazine plasma levels and effects.

Authors:  S H Curry; J H Marshall; J M Davis; D S Janowsky
Journal:  Arch Gen Psychiatry       Date:  1970-04

7.  Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electron capture detector.

Authors:  S H Curry
Journal:  Anal Chem       Date:  1968-07       Impact factor: 6.986

8.  Chlorpromazine: concentrations in plasma, excretion in urine and duration of effect.

Authors:  S H Curry
Journal:  Proc R Soc Med       Date:  1971-03

9.  More sensitive gas-chromatographic measurement of chlorpromazine in plasma.

Authors:  D R Flint; C R Ferullo; P Levandoski; B Hwang
Journal:  Clin Chem       Date:  1971-08       Impact factor: 8.327

10.  A comparative pharmacological study of a series of monohydroxylated and methoxylated chlorpromazine derivatives.

Authors:  A A Manian; D H Efron; M E Goldberg
Journal:  Life Sci       Date:  1965-12       Impact factor: 5.037

  10 in total
  12 in total

1.  Cerebrospinal fluid levels of chlorpromazine and it metabolites in schizophrenia.

Authors:  S Axelsson; S Jönsson; L Nordgren
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1975-12-31

Review 2.  Plasma level monitoring of antipsychotic drugs.

Authors:  T B Cooper
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

3.  Clinical significance of plasma chlorpromazine levels. II. Plasma levels of the drug, some of its metabolites and prolactin in patients receiving long-term phenothiazine treatment.

Authors:  T Kolakowska; D H Wiles; M G Gelder; A S McNeilly
Journal:  Psychopharmacology (Berl)       Date:  1976-08-26       Impact factor: 4.530

4.  Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.

Authors:  L T Kucharski; P Alexander; L Tune; J Coyle
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

5.  The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.

Authors:  K K Midha; J W Hubbard; S R Marder; E M Hawes; T Van Putten; G McKay; P R May
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Neuroendocrine tests during treatment with neuroleptic drugs: I. Plasma prolactin response to chlorpromazine challenge.

Authors:  T Kolakowska; S Fraser; M Franklin; J Knox
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  A mass fragmentographic method for the determination of chlorpromazine and two of its active metabolites in human plasma and CSF.

Authors:  G Alfredsson; B Wode-Helgodt; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1976-07-28       Impact factor: 4.530

8.  Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.

Authors:  L B Hansen; N E Larsen; P Vestergård
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Dopamine, serotonin and alpha-adrenergic receptor blocking activities in serum and their relationships to prolactin level in schizophrenic patients receiving long-term chlorpromazine treatment.

Authors:  T Nakahara; M Hirano; H Uchimura; M Saito; J S Kim; T Matsumoto; H Yokoo; M Shimomura; A Mukai
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses.

Authors:  B Wode-Helgodt; G Alfredsson
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.